[go: up one dir, main page]

MXPA05008441A - Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6. - Google Patents

Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.

Info

Publication number
MXPA05008441A
MXPA05008441A MXPA05008441A MXPA05008441A MXPA05008441A MX PA05008441 A MXPA05008441 A MX PA05008441A MX PA05008441 A MXPA05008441 A MX PA05008441A MX PA05008441 A MXPA05008441 A MX PA05008441A MX PA05008441 A MXPA05008441 A MX PA05008441A
Authority
MX
Mexico
Prior art keywords
group
sulfonylazaindole
hydroxytryptamine
heterocyclyl
ligands
Prior art date
Application number
MXPA05008441A
Other languages
English (en)
Inventor
Charles Bernotas Ronald
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05008441A publication Critical patent/MXPA05008441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuestos de formula (I) y al uso de los mismos para el tratamiento de un trastorno del sistema nervioso central relacionado con, o afectado por el receptor 5-HT6. En donde W es N o CR2; X es N o CR4; Y es N o CR5; Z es N o CR6; Q es N o CR7 con la condicion de que al menos uno y no mas de dos de X, Y, Z y Q deban ser N; R4, R5, R6, y R7 son cada uno independientemente H, halogeno, CN, COR8, OCO2R9, CO2R10, CONR11R13, NR14R15, OR16 o un grupo alquilo C1-C6, cicloalquilo C3-C7, arilo o heteroarilo cada uno opcionalmente sustituido o un grupo M que tiene la estructura de la formula (II), con la condicion de que al menos uno de R4, R5, R6 o R7 debe ser un grupo M y con la condicion ademas de que cuando W es CR2 y X o Z es N, entonces R7 bebe ser distinto a un grupo M.
MXPA05008441A 2003-02-14 2004-02-10 Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6. MXPA05008441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44751503P 2003-02-14 2003-02-14
PCT/US2004/003930 WO2004074286A1 (en) 2003-02-14 2004-02-10 Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
MXPA05008441A true MXPA05008441A (es) 2005-10-19

Family

ID=32908450

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008441A MXPA05008441A (es) 2003-02-14 2004-02-10 Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.

Country Status (12)

Country Link
US (2) US7259165B2 (es)
EP (1) EP1592690A1 (es)
JP (1) JP2006517966A (es)
CN (1) CN100482662C (es)
AR (1) AR043180A1 (es)
AU (1) AU2004213375A1 (es)
BR (1) BRPI0407493A (es)
CA (1) CA2515571A1 (es)
CL (1) CL2004000257A1 (es)
MX (1) MXPA05008441A (es)
TW (1) TW200418830A (es)
WO (1) WO2004074286A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
PT1956004E (pt) * 2002-03-27 2012-08-31 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
EP1497291B1 (en) * 2002-03-27 2006-11-22 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
TW200611695A (en) 2004-06-09 2006-04-16 Glaxo Group Ltd Pyrrolopyridine derivatives
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1778687A2 (en) * 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
GB2422830A (en) * 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) * 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) * 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
MX2007016463A (es) 2005-06-22 2008-03-04 Plexxikon Inc Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa.
JP2009504587A (ja) * 2005-08-09 2009-02-05 グラクソ グループ リミテッド ナンナビノイド受容体リガンドとしてのイミダゾピリジン誘導体
CN101282938A (zh) * 2005-08-15 2008-10-08 惠氏公司 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物
RU2008112313A (ru) * 2005-09-01 2009-10-10 Эррэй Биофарма Инк. (Us) Соединения ингибиторы raf и способы их применения
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1931668A2 (en) * 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
KR20080068127A (ko) * 2005-12-15 2008-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｃ]피리딘 유도체
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
EP2001865A1 (en) * 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
MX2008013206A (es) * 2006-04-19 2008-10-22 Abbott Gmbh & Co Kg Compuestos heterociclicos adecuados para el tratamiento de trastornos que responden a modulacion del receptor de serotonina 5ht6.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
BRPI1008709B8 (pt) 2009-04-03 2021-05-25 Hoffmann La Roche dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
BR112012028055A2 (pt) * 2010-05-06 2019-09-24 Merck Sharp & Dohme composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN103613591B (zh) * 2012-09-29 2016-04-13 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
US10106452B2 (en) 2014-02-14 2018-10-23 Superior Fibers, Llc System and method of continuous glass filament manufacture
US10351462B1 (en) 2014-02-14 2019-07-16 Superior Fibers, Llc Method of manufacturing fiberglass filtration media
US9446978B2 (en) 2014-02-14 2016-09-20 Charles Douglas Spitler System and method for continuous strand fiberglass media processing
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
CN107531423B (zh) 2015-03-27 2020-07-10 高级纤维有限责任公司 用于处理玻璃纤维介质的设备
MX388281B (es) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamiento de un trastorno conductual del sueño rem.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69725337T2 (de) 1996-11-26 2004-07-15 Nps Allelix Corp., Mississauga 5-cyclo-indolverbindungen als 5-ht1d rezeptor liganden
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
ATE375990T1 (de) 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
MXPA02001473A (es) * 1999-08-12 2003-07-21 Nps Allelix Corp Azaindoles que tienen afinidad con el receptor de serotonina.
EP1326830A1 (en) * 2000-10-20 2003-07-16 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
JP2004520325A (ja) * 2000-12-22 2004-07-08 ワイス ５−ヒドロキシトリプトアミン−６−リガンドとしてのヘテロシクリルアルキルインドールまたは−アザインドール化合物
DE60218037T2 (de) * 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag Neue indolderivate mit affinität zum 5-ht6-rezeptor
JP2005527463A (ja) * 2001-08-07 2005-09-15 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
PT1956004E (pt) 2002-03-27 2012-08-31 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
EP1497291B1 (en) * 2002-03-27 2006-11-22 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200403243A (en) * 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
JP2006517966A (ja) 2006-08-03
US7259165B2 (en) 2007-08-21
CN100482662C (zh) 2009-04-29
EP1592690A1 (en) 2005-11-09
CL2004000257A1 (es) 2005-01-14
WO2004074286A1 (en) 2004-09-02
US20080015201A1 (en) 2008-01-17
TW200418830A (en) 2004-10-01
BRPI0407493A (pt) 2006-02-14
CN1777602A (zh) 2006-05-24
CA2515571A1 (en) 2004-09-02
AU2004213375A1 (en) 2004-09-02
US7576087B2 (en) 2009-08-18
US20040167030A1 (en) 2004-08-26
AR043180A1 (es) 2005-07-20

Similar Documents

Publication Publication Date Title
MXPA05008441A (es) Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
GEP20084552B (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
UA91535C2 (en) IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS
NO20091708L (no) Nye kinase inhibitorer
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MX2011008601A (es) Compuestos de alquilamido y usos de los mismos.
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
UA101299C2 (uk) Сполуки, що мають активність стосовно рецепторів м1, та їх застосування в медицині
MX2008013053A (es) Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6.
NO20080937L (no) Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
NO20050937L (no) Indolin-derivater substituert i stilling 6, fremstilling og andvendelse derav som medikamenter
ATE356131T1 (de) Tricyclische imidazopyridine
MXPA03011769A (es) Derivados de heteroarilo novedosos, su preparacion y uso.

Legal Events

Date Code Title Description
FG Grant or registration